TherapeuticsMD is developing new products to treat diseases and conditions in key women’s healthcare categories, with a short-term pipeline focus on new and improved hormone replacement therapies. Three novel development programs are currently ongoing.
TX-001HR (estradiol + progesterone)
TX-001HR is the first and only combination drug candidate designed to replace the exact 17ß-estradiol and progesterone hormones the body has stopped producing and to treat the symptoms of menopause due to the reduction.
For more information on TX-001HR, please click here.
TX-002HR is a progesterone product under development for the treatment of secondary amenorrhea.
For more information on TX-002HR, please click here.
TX-003HR is a 17β estradiol product under development in postmenopausal women for the treatment of moderate to severe vasomotor symptoms due to menopause. These symptoms include hot flashes, night sweats, sleep disturbances, and vaginal dryness.
For more information on TX-003HR, please click here.
TX-004HR is a 17β estradiol product under development for treatment of postmenopausal women for vulvar and vaginal atrophy. It is a unique delivery design using a VagiCap™ softgel capsule technology to provide easy, simple delivery.
For more information on TX-004HR, please click here.